arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

Perspective Therapeutics, Inc.

CATX
$3.00 ▲ +0.03 (+1.01%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
63 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
53
Health
Fair
Neutral
auto_awesome

Analytical Summary

Perspective Therapeutics, Inc. demonstrates solid fundamentals with strength in Debt to Equity. Consider comparing against peers in the Healthcare sector before making investment decisions.

Market Cap $310.8M
Dividend Yield
Revenue Growth None
Op. Margin None
ROIC -6.4%
FCF / Share $-0.37
Trailing P/E
Price / Book 1.0x
FCF Yield
Debt / Equity 0.00
info Valuation on last close. End-of-day price, Aug 7, 2026.

63-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$2.19M
↑ +27.3%
Net Income Profit after all expenses
$-26.19M
↓ -44.1%
Operating Margin Operating profit as % of sales
-482.1%
↓ -96.7%
FCF / Share Free cash flow per share
$-0.37
↓ -2.0%
Long-Term Debt Long-term obligations
$1.61M
↓ -0.9%
trending_up

Bullish Indicators

  • Debt to EquityDebt to Equity is in the top quartile (lower is better)
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
17
Financial Health
94
Cash Quality
62

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 16 years · 63 quarters